US20100173288A1 - Serum/plasma micronas and uses thereof - Google Patents

Serum/plasma micronas and uses thereof Download PDF

Info

Publication number
US20100173288A1
US20100173288A1 US12/302,196 US30219607A US2010173288A1 US 20100173288 A1 US20100173288 A1 US 20100173288A1 US 30219607 A US30219607 A US 30219607A US 2010173288 A1 US2010173288 A1 US 2010173288A1
Authority
US
United States
Prior art keywords
mir
probe
diseases
subject
serum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/302,196
Other languages
English (en)
Inventor
Chenyu Zhang
Junfeng Zhang
Xi Chen
Yi Ba
Jiangning Chen
Jin Wang
Ke Zeng
Hongjie ZHANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Micromedmark Biotech Co Ltd
Original Assignee
Jiangsu Micromedmark Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Micromedmark Biotech Co Ltd filed Critical Jiangsu Micromedmark Biotech Co Ltd
Assigned to JIANGSU MINGMA BIOTECH CO., LTD. reassignment JIANGSU MINGMA BIOTECH CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHEN, XI, ZHANG, HONGJIE, ZHANG, JUNFENG, WANG, JIN, BA, YI, CHEN, JIANGNING, ZENG, KE, ZHANG, CHEN-YU
Assigned to JIANGSU MINGMA BIOTECH CO., LTD. reassignment JIANGSU MINGMA BIOTECH CO., LTD. RE-RECORD TO CORRECT THE EXECUTION DATE OF THE FIRST ASSIGNOR, PREVIOUSLY RECORDED ON REEL 021885 FRAME 0751. Assignors: CHEN, XI, ZHANG, HONGJIE, ZHANG, JUNFENG, WANG, JIN, BA, YI, CHEN, JIANGNING, ZENG, KE, ZHANG, CHEN-YU
Publication of US20100173288A1 publication Critical patent/US20100173288A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Definitions

  • the present invention relates to microRNAs and uses thereof, more specifically, to serum/plasma microRNAs and the uses of serum/plasma microRNAs for diagnosis and differential diagnosis of diseases, prediction of complication occurrence and malignant disease relapse, evaluation of therapeutic effects, screening of pharmaceutical active ingredients, assessment of drug efficacy, forensic authentication and prohibited drug inspection and the like.
  • various acute/chronic infectious diseases e.g. viral diseases such as viral influenza, viral hepatitis, AIDS, SARS, bacterial diseases such as tuberculosis, bacterial pneumonia, and other acute/chronic infectious diseases caused by various pathogenic microorganisms; other acute/chronic diseases such as diseases of respiratory system, diseases of immune system, diseases of blood and hematopoietic system, diseases of circulatory system such as cardio-cerebrovascular diseases, metabolic diseases of endocrine system, diseases of digestive system, diseases of nervous system, diseases of urinary system, diseases of reproductive system and diseases of locomotor system.
  • viral diseases such as viral influenza, viral hepatitis, AIDS, SARS, bacterial diseases such as tuberculosis, bacterial pneumonia, and other acute/chronic infectious diseases caused by various pathogenic microorganisms
  • other acute/chronic diseases such as diseases of respiratory system, diseases of immune system, diseases of blood and hematopoietic system, diseases of circulatory system such as cardio-cerebrovascular diseases,
  • tumor marker e.g. alphafetoprotein, lactic dehydrogenase and carcinoembryonic antigen have been widely used in clinic.
  • these disease markers are far from meeting the needs of early diagnosis for cancer for the following two main reasons: (1) the sensitivity and specificity for the above-mentioned disease markers are relatively low, thus their detection results cannot be used as a diagnostic indicator of disease; (2) the early diagnosis rate of disease shall be positively correlative with the therapeutic effects.
  • MicroRNAs are defined as a kind of non-coding single-stranded small RNA moleculars of approximately from 19 to 23 nucleotides in length. They are highly conservative in evolution; and are closely related to many normal physiological activities of animals such as development process, tissue differentiation, cell apoptosis and energy metabolism; in addition, bear close relation with the occurrence and development of many diseases. Recent studies show that the expression levels of several microRNAs in chronic lymphocytic leukemia and Burkitt lymphoma are on average down-regulated to various extents; and that by analyzing and comparing the expressions of microRNAs in tissues of human lung cancer and human breast cancer, the expression levels of several tissue specific microRNAs have changed relative to normal tissues.
  • microRNAs affect the occurrence and development of cardio-cerebrovascular diseases such as myocardial hypertrophy, heart failure, atherosclerosis, and are closely relative to metabolic diseases such as Diabetes II. These experimental results indicate that there exists inevitable connection between the expression and specificity changes of microRNAs and the occurrence and development of diseases.
  • microRNAs have some associations with diseases.
  • the changes of microRNAs may be the cause of diseases. This is because both the inhibitor and the promoter of diseases may be target sites for microRNAs. If the expression of microRNA itself is disturbed, e.g., the expression level of microRNA which is originally to inhibit disease promoters decreases or the expression level of microRNA which is to inhibit disease inhibitor increases, its end results will both lead to changes in the expression of downstream genes and the overall disorder of some pathways, further inducing the occurrence of diseases. Secondly, the changes of microRNAs may also result from diseases.
  • microRNAs can be completely regarded as a kind of new disease markers, the specificity changes of which inevitably correlate with the occurrence and development of diseases. Meanwhile, microRNA can also be used as a potential drug target, and it may greatly alleviate the occurrence and development of diseases by inhibiting the up-regulated microRNAs and overexpressedly down-regulated microRNAs in the course of a disease.
  • the inventor has carried out the research in the relevant fields of using microRNAs as disease markers, for instance, choosing colonic carcinoma which ranks forth in the incidence of malignant tumor as the research object.
  • the research suggests that, during the process of colon benign polyps developing into malignant tumor, some microRNAs exhibit specificity changes, thereby a more sensitive and accurate method for the early diagnosis of colonic carcinoma having been set up through detecting the specific changes in microRNAs.
  • the sampling for tissue specimen is not easy, the wide application of this method in clinics is limited.
  • the inventor focuses the research on the blood which is relatively easy to obtain and even can be collected via routine physical examination. Blood will circulate to all tissues in body and convey nutrients to cells whilst scavenging waste materials; therefore, blood is able to reflect the physiological pathology of the whole organism and its detection results is an indicator of human health.
  • microRNAs consisting of from 19 to 23 nucleotides, possess specificity and relative stability in structure and hence are very likely present in serum/plasma.
  • microRNAs are a new type of disease markers, it is anticipated that by studying whether or not microRNAs are present in serum/plasma, whether or not they can be detected and the connection between microRNAs and diseases, a new technology is established for the early disease diagnosis, disease identification as well as monitoring and controlling of course of diseases, prediction of malignant disease relapse and prognosis and complication occurrence, assessment of drug efficacy, guide of medication, individualized treatment, screening of active ingredients of Chinese Traditional Medicines, population taxonomy, etc., by use of the microRNAs stably existing in serum/plasma as well as their specificity changes.
  • the present invention provides a combination of microRNAs for evaluating physiological and/or pathological condition in a subject, wherein the combination comprises all detectable microRNAs stably existing in the serum/plasma of the subject.
  • the present invention further provides a method for evaluating physiological and/or pathological condition in a subject, wherein the method comprises determining all detectable microRNAs stably existing in the serum/plasma of the subject.
  • all detectable microRNAs stably existing in serum/plasma of a subject may be all mature microRNAs in human serum/plasma, specifically include let-7a, let-7b, let-7c, let-7d, let-7e, let-7f, let-7g, let-7i, miR-1, miR-100, miR-101, miR-103, miR-105, miR-106a, miR-106b, miR-107, miR-10a, miR-10b, miR-122a, miR-124a, miR-125a, miR-125b, miR-126, miR-126*, miR-127, miR-128a, miR-128b, miR-129, miR-130a, miR-130b, miR-132, miR-133a, miR-133b, miR-134, miR-135a, miR-135b, miR-136, miR-137, miR-138, miR-139, miR
  • the aforesaid method for determining all detectable microRNAs stably existing in serum/plasma of a subject is one or more selected from the group consisting of RT-PCR method, Real-time PCR method, Northern blotting method, RNase protection assay, Solexa sequencing technology and biochip method.
  • the aforesaid RT-PCR method includes the following steps:
  • the aforesaid real-time PCR method includes the following steps:
  • the present invention further provides a kit for evaluating physiological and/or pathological condition of a subject, wherein the kit comprises the tools for determining all detectable microRNAs stably existing in the serum/plasma of the subject.
  • the kit may comprises the primers of all mature microRNAs in human serum/plasma, specifically comprises the primers of let-7a, let-7b, let-7c, let-7d, let-7e, let-7f, let-7g, let-7i, miR-1, miR-100, miR-101, miR-103, miR-105, miR-106a, miR-106b, miR-107, miR-10a, miR-10b, miR-122a, miR-124a, miR-125a, miR-125b, miR-126, miR-126*, miR-127, miR-128a, miR-128b, miR-129, miR-130a, miR-130b, miR-132, miR-133a, miR-133b, miR-134
  • the present invention also provides a biochip for evaluating physiological and/or pathological condition of a subject, wherein the biochip contains the components for determining all detectable microRNAs stably existing in the serum/plasma of the subject.
  • the biochip may also contain the probes for all mature microRNAs in human serum/plasma.
  • the probes specifically include the probes as shown in Table 1.
  • the said evaluation of the physiological and/or pathological condition of a subject is to determine the physiological and/or pathological condition of the subject after being administrated a test sample, which is specifically useful for screening the test sample for the activities on the prevention and/or treatment of diseases;
  • the said evaluation of the physiological and/or pathological condition of a subject is to diagnose and/or differentially diagnose the diseases of the subject;
  • the said evaluation of the physiological and/or pathological condition of a subject is to evaluate the effectiveness of the treatment on the diseases of the subject;
  • the said evaluation of the physiological and/or pathological condition of a subject is to predict the disease occurrence of the subject, which is specifically the occurrence of complications and/or the relapse of malignant diseases;
  • the above-mentioned combinations, methods, kits or biochips can also be useful for detecting the subject for prohibited drugs-taking.
  • the above-mentioned diseases include a variety of tumors; various acute/chronic infectious diseases, e.g. viral diseases such as viral influenza, viral hepatitis, AIDS, SARS, bacterial diseases such as tuberculosis, bacterial pneumonia, and other acute/chronic infectious diseases caused by various pathogenic microorganisms; other acute/chronic diseases such as diseases of respiratory system, diseases of immune system, diseases of blood and hematopoietic system, diseases of circulatory system such as cardio-cerebrovascular diseases, metabolic diseases of endocrine system, diseases of digestive system, diseases of nervous system, diseases of urinary, diseases of reproductive system and diseases of locomotor system.
  • viral diseases such as viral influenza, viral hepatitis, AIDS, SARS, bacterial diseases such as tuberculosis, bacterial pneumonia, and other acute/chronic infectious diseases caused by various pathogenic microorganisms
  • other acute/chronic diseases such as diseases of respiratory system, diseases of immune system, diseases of blood and hematopoietic system
  • the above-mentioned serum/plasma derives from the living bodies, tissues, organs and/or corpuses of the subject.
  • the problems to be solved by the present invention include: (1) analyzing and identifying the microRNA molecules and their stability in serum/plasma of a variety of animals such as human, mice and rats; (2) studying the specificity changes of microRNAs in serum/plasma during the course of various clinical diseases including a variety of tumors; various acute/chronic infectious diseases, e.g.
  • viral diseases such as viral influenza, viral hepatitis, AIDS, SARS, bacterial diseases such as tuberculosis, bacterial pneumonia, and other acute/chronic infectious diseases caused by various pathogenic microorganisms; other acute/chronic diseases such as diseases of respiratory system, diseases of immune system, diseases of blood and hematopoietic system, diseases of circulatory system such as cardio-cerebrovascular diseases, metabolic diseases of endocrine system, diseases of digestive system, diseases of nervous system, diseases of urinary system, diseases of reproductive system and diseases of locomotor system; (3) detecting the respective changes of microRNAs in serum/plasma for different diseases through biochip and sequencing technology for microRNAs in serum/plasma; (4) screening a kind of microRNA molecules in serum/plasma which have relatively greater differential expression during the course of diseases and normal physiological conditions to develop detection technologies for serum/plasma microRNAs, and then preparing biochips and diagnostic kits useful for disease diagnosis etc.
  • viral diseases such as viral influenza, viral hepatitis, AIDS, SARS,
  • the present invention analyzes and identifies the existence of microRNA molecules in serum/plasma of various animals such as human, mice and rats through the methods of RT-PCR, Real-time PCR, Northern blotting, RNase protection assay, Solexa sequencing technology and biochip.
  • the stability of microRNAs in serum/plasma is studied by comparing the changes of microRNAs by the effect of DNase and RNase.
  • the existence of serum/plasma microRNAs molecules and the correctness of their sequences are further verified through sequencing and comparing the PCR products of serum/plasma microRNAs.
  • RT-PCR method collecting serum/plasma samples; conducting reverse transcription reaction on serum/plasma samples to prepare cDNA samples, or extracting total RNA of serum/plasma with Trizol reagent and then conducting reverse transcription reaction so as to prepare cDNA samples; designing a primer through mature microRNAs so as to conduct PCR reaction; carrying out agarose gel electrophoresis with the products of PCR; and observing and taking photographs for the results under ultraviolet lamp after EB staining.
  • Real-time PCR method collecting serum/plasma samples; conducting reverse transcription reaction on serum/plasma samples to prepare cDNA samples, or extracting total RNA of serum/plasma with Trizol reagent and then conducting reverse transcription reaction so as to prepare cDNA samples; designing a primer of PCR through mature microRNAs and adding a fluorescent probe EVA GREEN so as to carry out PCR reaction; analyzing and processing the data and then comparing the results.
  • Northern blotting method collecting serum/plasma samples; extracting total RNA of serum/plasma with Trizol reagent; conducting denaturing PAGE-electrophoresis and membrane transferring experiment; preparing isotope-labeled microRNA probes; conducting membrane hybridization reaction; detecting the isotope signal for results such as using phosphor-screen scanning technology.
  • RNase protection assay firstly synthesizing an antisense RNA probe, labelling it with isotopes and purifying it; collecting serum/plasma samples and extracting RNA; dissolving the extracted DNA in a hybrid buffer and then adding an antisense RNA probe so as to conduct hybridization reaction; adding a RNase digestion solution to initate reaction; subjecting the resultant material to electrophoresis and radioautography; and analyzing the results.
  • Solexa sequencing technology collecting serum/plasma samples; extracting total RNA of serum/plasma with Trizol reagent; conducting PAGE-electrophoresis to recover RNA molecules of 17 ⁇ 27 nt; enzyme-linking adaptor prime to the 3′ and 5′ end of small RNA molecules respectively; conducting RT-PCR reaction prior to sequencing; and analyzing and processing the data.
  • Biochip method arraying a library of all over 500 mature microRNAs to prepare biochips; collecting serum/plasma samples; extracting total RNA of serum/plasma; separating microRNAs by column separation; fluorescently-labelling microRNAs by use of T4 RNA ligase; conducting hybridization reaction with a biochip; and detecting and analyzing the data.
  • viral diseases such as viral influenza, viral hepatitis, AIDS, SARS, bacterial diseases such as tuberculosis, bacterial pneumonia, and other acute/chronic infectious diseases caused by various pathogenic microorganisms; other acute/chronic diseases such as diseases of respiratory system, diseases of immune system, diseases of blood and hematopoietic system, diseases of circulatory system such as cardio-cerebrovascular diseases, metabolic diseases of endocrine system, diseases of digestive system, diseases of nervous system, diseases of urinary system, diseases of reproductive system and diseases of locomotor system); Biochips of serum/plasma microRNAs are prepared to determine the changes of serum/plasma microRNAs in different diseases, and meanwhile, Solexa sequencing and analysis on microRNAs in serum/plasma in different diseases are conducted.
  • viral diseases such as viral influenza, viral hepatitis, AIDS, SARS, bacterial diseases such as tuberculosis, bacterial pneumonia, and other acute/chronic infectious diseases caused by various pathogenic microorganisms
  • microRNAs with disease-related specificity changes are screened out, their primers are collected into a PCR kit (RT-PCR or Real-time PCR) to prepare a disease-diagnostic kit, or their reverse complementary sequences are dripped on chips as probes so as to prepare the biochips for detecting serum/plasma microRNAs specific for a certain disease.
  • RT-PCR Real-time PCR
  • serum/plasma microRNAs based on biochips of serum/plasma microRNAs and diagnostic kits skillfully combines the peculiar properties of serum/plasma microRNAs with conventional molecular biology detection technique together, which can rapidly analyze the respective constitution of serum/plasma microRNAs in respect of various diseases with high throughput and hence be of extremely clinical practicality. Since the changes of physiological conditions in organs and tissues will cause the constitutional changes of serum/plasma microRNAs, serum/plasma microRNAs can be used as “fingerprints for diseases” to realize early diagnosis of diseases.
  • serum/plasma microRNAs possess certain advantages such as extensive spectrum for detection, high sensitivity, low cost for detection, convenient sampling, easy preservation for samples (preserving serum/plasma at ⁇ 20° C. will do), etc. This method can be widely used in general survey of diseases and other relevant tasks and has become an efficient means for early diagnosis of diseases.
  • serum/plasma microRNAs will improve the low-specificity and low-sensitivity caused by individual differences which single markers are difficult to overcome, and notably increase the clinical detection rate of diseases so as to realize early diagnosis of diseases.
  • FIG. 1 shows the RT-PCR result of partial microRNAs directly detected in the serum of a normal person.
  • FIG. 2 shows the RT-PCR results of the microRNAs in the RNA extracted from the serum of a normal person.
  • U6 is a snRNA with a molecular weight of 100 bp, serving as an internal reference molecule in microRNAs experiments.
  • the rest of 12 microRNAs are each miR-181a(181a), miR-181b(181b), miR-223(223), miR-142-3p(142-3p), miR-142-5p(142-5p), miR-150(150) with blood cell specificity; miR-1(1), miR-133a(133a), miR-206(206) from cardiac muscles and skeletal muscles; miR-9(9), miR-124a(124a) from brain tissues; and miR-122a (122a) from liver.
  • FIG. 3 shows the RT-PCR results of partial micro-RNAs directly detected in the serum of mouse, rat, fetal bovine, calf and horse respectively.
  • FIG. 4 shows the variable quantity of the partial microRNAs in the serum of a patient suffering from the shown diseases compared with microRNAs in the serum of a normal person.
  • FIG. 5 shows the ratio between the quantities of macroRNAs and microRNAs in blood cells and serum.
  • FIG. 6 shows the enzyme digested results of macroRNAs and microRNAs.
  • RT-PCR By using RT-PCR technique, it is found and proved that there stably exist various microRNAs in serum/plasma of both human beings and animals, and that their expression levels are considerably high.
  • the specific RT-PCR steps are as follows:
  • This operation has two options: one is to directly conduct reverse transcription reaction using 10 ⁇ l of serum/plasma; the other is to firstly extract the total RNA from serum/plasma (usually, about 10 ⁇ g of RNA can be enriched from 10 ml of serum/plasma) with Trizol reagent (Invitrogen Co.), subsequently obtain cDNA through RNA reverse transcription reaction.
  • the reaction system of reverse transcription includes 4 ⁇ l 5 ⁇ AMV buffer, 2 ⁇ l 10 mM each dNTP mixture (Takara Co.), 0.5 ⁇ l RNase Inhibitor (Takara Co.), 2 ⁇ l AMY (Takara Co.) and 1.5 ⁇ l gene specific reverse primers mixtures.
  • the reaction steps successively include 15 minutes of incubation at 16° C., 1 hour of reaction at 42° C. and 5 minutes of incubation at 85° C.;
  • the cDNA is diluted by 1/50. To 1 ⁇ l diluted cDNA are added 0.3 ⁇ l Taq polymerase (Takara Co.), 0.2 ⁇ l 10 ⁇ M forward primer, 0.20 ⁇ l 10 ⁇ M universal reverse primer, 1.2 ⁇ l 25 mM MgCl 2 , 1.6 ⁇ l 2.5 mM each dNTP mixture (Takara Co.), 2 ⁇ l 10 ⁇ PCR buffer, 13.5 ⁇ l H 2 O, and PCR reaction is conducted in the 20 ⁇ l system. The PCR reaction is done under the following conditions: one cycle at 95° C. for 5 mins followed by 40 cycles at 95° C. for 15 seconds and 60° C. for 1 minute. 10 ⁇ l PCR product is subjected to 3% Agarose Gel Electrophoresis, which is observed under ultraviolet lamp after EB staining.
  • FIG. 1 shows the experimental results of RT-PCR directly conducted on the serum of normal persons.
  • the all over 500 mature microRNAs in human being are selected for conducting RT-PCR reaction, of which 12 microRNAs are shown in FIG. 1 and each miR-181a, miR-181b, miR-223, miR-142-3p, miR-142-5p, miR-150 with is blood cell specificity; miR-1, miR-133a, miR-206 from cardiac muscles and skeletal muscles; miR-9 and miR-124a from brain tissues; and miR-122a from liver.
  • RNA is firstly extracted from the serum of normal persons, then all over 500 mature microRNAs of human are selected for PCR experiment. As shown in FIG. 2 , the results of FIG. 2 is quite consistent with that of FIG. 1 , the singleness of the PCR products indicating that both two assays can detect the expression and level of the microRNAs in people's serum/plasma, and proving that there stably exist microRNAs of various tissues sources in people's serum/plasma.
  • microRNAs in serum/plasma are conducted to study the specific variation of microRNAs quantity in serum/plasma during the course of various diseases, including various tumors, various acute and chronic infectious diseases, e.g. viral diseases such as viral influenza, viral hepatitis, AIDS, SARS, bacterial diseases such as tuberculosis, bacterial pneumonia, and other acute and chronic infectious diseases caused by various pathogenic microorganisms; other acute and chronic diseases such as diseases of respiratory system, diseases of immune system, diseases of blood and hematopoietic system, diseases of circulatory system such as cardio-cerebrovascular disease, metabolic diseases of endocrine system, diseases of digestive system, diseases of nervous system, diseases of urinary system, diseases of reproductive system and diseases of locomotor system.
  • viral diseases such as viral influenza, viral hepatitis, AIDS, SARS, bacterial diseases such as tuberculosis, bacterial pneumonia, and other acute and chronic infectious diseases caused by various pathogenic microorganisms
  • other acute and chronic diseases such as diseases of respiratory system,
  • the experimental principles and experimental steps of quantitative PCR are basically the same as those of RT-PCR, with the only difference between them being the addition of a fluorescent dye EVA GREEN in the process of PCR.
  • An ABI Prism 7300 fluorescent quantitative PCR instrument is used to conduct PCR reaction under the following conditions: one cycle at 95° C. for 5 mins followed by 40 cycles at 95° C. for 15 seconds and 60° C. for 1 minute.
  • the data processing method used is ⁇ CT method, wherein CT is the number of cycles when the reaction reaches the threshold.
  • Reverse transcription reactions are directly conducted on serum/plasma samples of a patient and those of a normal person, and the quantities of microRNAs contained in each sample of serum/plasma are compared through quantitative PCR reactions.
  • FIG. 4 shows the quantitative PCR experimental results of microRNAs within serum of patients and normal persons which include the above-mentioned miR-181a, miR-181b, miR-223, miR-142-3p, miR-142-5p, miR-150 with blood cell specificity; miR-1, miR-133a, miR-206 from cardiac muscles and skeletal muscles; miR-9, miR-124a from brain tissues; and miR-122a from liver.
  • the ratio of the microRNAs quantity in serum between normal persons and patients suffering from aplastic anemia, breast cancer, osteosarcoma, CNS (Central Nervous System) lymphoma, diabetes are respectively up-regulated or down-regulated, and the variation extent of the microRNAs quantity from the same tissue source differs in patients with different diseases, indicating that there is specificity variation of microRNAs quantity in the serum/plasma of patients with different diseases. They can be taken as a type of novel markers for disease diagnosis.
  • microRNAs and macroRNAs are found that there is an abundant content of microRNAs in serum. See FIG. 5 .
  • the quantity of macroRNAs in blood cells is at least tens times that in serum; while the quantity of microRNAs in serum remains the same as that in blood cells except the microRNAs with blood cell specificity. Therefore, serum/plasma will specifically enrich small molecule RNAs, especially microRNAs.
  • microRNAs are to some extent able to resist the action of endonuclease, which is possibly one of the reasons why microRNAs can stably exist in serum/plasma.
  • Total RNAs extracted from cultured cell line are processed with endonuclease RNase A and the remaining quantity of macroRNAs and microRNAs are then detected.
  • FIG. 6 it is found that microRNAs can to some extent resist the degradation of endonuclease while the macroRNAs are substantially completely cut off. Therefore microRNAs can stably exist in serum/plasma.
  • microRNAs could be well applied in clinical test.
  • a biochip of serum/plasma microRNAs is fabricated to verify the reliability of a kind of serum/plasma microRNAs probes relating to diseases which are selected through quantitative PCR method.
  • the biochip contains all microRNAs probes that can be normally detected in people's serum/plasma, constituting a probe library. See Table 1.
  • some probes of the probe library are put together to construct a probe collection which makes it possible to quantitatively detect the variation of microRNAs in the specific conditions.
  • the collection of probes that have interaction with microRNAs of numbers 17-5p, 21, 103, 106a, 107, 126*, 143, 145, 150, 155 and 210 is used.
  • the collection of probes that have interaction with microRNAs of numbers 21, 23a, 23b, 24, 27a, 27b, 125b, 195, 199a, 214, 217, 133a is used.
  • the chip can also do high-throughput screening of the probes of microRNAs varying stably in serum/plasma, and diseases can be predicted and diagnosed based on the overall variation of microRNAs in serum/plasma.
  • Sequencing method or quantitative PCR method is firstly used to determine that there is more than one copy of microRNAs in serum/plasma, and then reverse complementary probes of these microRNAs are synthesized, after which these probes are spotted on a chemically-modified slide in a size of 75 ⁇ 25 mm using a biochip microarrayer SmartArrayTM.
  • the samples spotted on the chip also include U6 and tRNA as internal standard, artificially-prepared external standard in length of 30 bases, Hex as positive control etc.
  • the entire lattice is divided into 4 sub-lattices and each sub-lattice has 23 rows and 21 columns, wherein the spot distance is 185 mm and the spot diameter is about 130 ⁇ m and each probe was repeatly spotted for 3 times.
  • the operational procedure of the biochip is: (1) extracting the total RNA from serum/plasma and detecting its quality through formaldehyde denaturing gel electrophoresis; (2) separation of microRNAs: 50-100 ⁇ g total RNA is taken to separate microRNAs from total RNA with Ambion's miRNA Isolation Kit (Cat #.
  • microRNAs samples are fluorescently-labeling with T4 RNA ligase, then precipitated with absolute ethanol, and then blown to dryness for chip hybridization;
  • hybridization and cleaning RNA is dissolved into 16 ⁇ L hybridizing solution (15% formamide, 0.2% SDS, 3 ⁇ SSC and 50 ⁇ Denhardt's solution), and hybridized at 420 overnight. After completion of the hybridization, it is washed in a solution containing 0.2% SDS and 2 ⁇ SSC at about 42° C. for 4 minutes, and then washed in a solution containing 0.2 ⁇ SSC at room temperature for 4 minutes.
  • the slides can be used for scanning immediately after being dried; (5) chip scanning: the chip is scanned with two-channel laser scanner LuxScan 10K/A; (6) data extracting and analysis: the chip image is analyzed with an image analyzing software LuxScan 3.0, the image signal is transformed into digital signal, and finally differentially-expressed genes are analyzed and selected with SAM method.
  • a biochip is prepared as above by using a kind of serum/plasma microRNAs probes which express greatly differently under disease condition and normal physiological condition double-verified by quantitative PCR technique and biochip technique.
  • this chip simplifies the probe library, thereby greatly reducing the manufacturing cost and production time of the chip, and hence is easy to prepare. Meanwhile it increases the pertinence and practicability of chip.
  • the application of the chip in practice can detect diseases in an early phase with only need of the serum/plasma of a patient and no need of other tissues, which helps guide the diagnosis and treatment.
  • microRNAs kits useful for diagnosis, prediction of complication occurrence and malignant disease relapse, evaluation of therapeutic effects, screening of pharmaceutical active ingredients, assessment of drug efficacy, forensic authentication and prohibited drug inspection, etc. of all diseases are based on quantitative PCR technique and semi-quantitative PCR technique and biochip technique.
  • the above-mentioned diseases include various tumors; various acute/chronic infectious diseases, e.g.
  • viral diseases such as viral influenza, viral hepatitis, AIDS, SARS, bacterial diseases such as tuberculosis, bacterial pneumonia, and other acute/chronic infectious diseases caused by various pathogenic microorganisms; other acute/chronic diseases such as diseases of respiratory system, diseases of immune system, diseases of blood and hematopoietic system, diseases of circulatory system such as cardio-cerebrovascular diseases, metabolic diseases of endocrine system, diseases of digestive system, diseases of nervous system, diseases of urinary system, diseases of reproductive system and diseases of locomotor system.
  • viral diseases such as viral influenza, viral hepatitis, AIDS, SARS, bacterial diseases such as tuberculosis, bacterial pneumonia, and other acute/chronic infectious diseases caused by various pathogenic microorganisms
  • other acute/chronic diseases such as diseases of respiratory system, diseases of immune system, diseases of blood and hematopoietic system, diseases of circulatory system such as cardio-cerebrovascular diseases, metabolic diseases of endocrine system, diseases of digestive
  • Sequencing method or quantitative PCR method is firstly used to determine that there is more than one copy of microRNAs in serum/plasma. Then, a kind of serum/plasma microRNAs that have a big difference between the expression levels in disease condition and in normal physiological condition are screened out through the techniques of quantative PCR and biochip, which are taken as an indicator for predicting whether canceration or other disease occurs and diagnosing the pathological degree. Finally the number of screened corresponding serum/plasma microRNAs of each disease would be controlled to over ten to tens, which is the optimized condensement of the chip-probe library.
  • the kit contains a batch of serum/plasma microRNAs primers, Taq polymerase, dNTP, etc.
  • the value of the kit lies in making it possible to detect the changing trend of microRNAs through the most simplified probe library and with only need of serum/plasma and no need of any other tissue samples, and further predict the probability of occurrence of diseases or diagnose the pathological phase of diseases based on this changing trend detected.
  • the application of this kit in practice can increase the possibility of discovering diseases in an early phase, which helps guide the diagnosis and treatment of diseases.
US12/302,196 2007-11-02 2007-12-06 Serum/plasma micronas and uses thereof Abandoned US20100173288A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN200710134620.4 2007-11-02
CN2007101346204A CN101424640B (zh) 2007-11-02 2007-11-02 血清中微小核糖核酸的检测方法和用于检测的试剂盒、生物芯片及其制作和应用方法
PCT/CN2007/003463 WO2009055979A1 (fr) 2007-11-02 2007-12-06 Micro-arn dans le sérum/plasma sanguin et leurs utilisations

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2007/003463 A-371-Of-International WO2009055979A1 (fr) 2007-11-02 2007-12-06 Micro-arn dans le sérum/plasma sanguin et leurs utilisations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/144,127 Division US10077477B2 (en) 2007-11-02 2013-12-30 Serum/plasma MicroRNAs and uses thereof

Publications (1)

Publication Number Publication Date
US20100173288A1 true US20100173288A1 (en) 2010-07-08

Family

ID=40590521

Family Applications (3)

Application Number Title Priority Date Filing Date
US12/302,196 Abandoned US20100173288A1 (en) 2007-11-02 2007-12-06 Serum/plasma micronas and uses thereof
US14/144,127 Active US10077477B2 (en) 2007-11-02 2013-12-30 Serum/plasma MicroRNAs and uses thereof
US15/171,737 Active US10011880B2 (en) 2007-11-02 2016-06-02 Serum/plasma MicroRNAs and uses thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
US14/144,127 Active US10077477B2 (en) 2007-11-02 2013-12-30 Serum/plasma MicroRNAs and uses thereof
US15/171,737 Active US10011880B2 (en) 2007-11-02 2016-06-02 Serum/plasma MicroRNAs and uses thereof

Country Status (6)

Country Link
US (3) US20100173288A1 (zh)
EP (1) EP2133431B1 (zh)
CN (1) CN101424640B (zh)
DK (1) DK2133431T3 (zh)
IL (1) IL195324A (zh)
WO (1) WO2009055979A1 (zh)

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090246136A1 (en) * 2008-03-17 2009-10-01 Andrew Williams Identification of micro-rnas involved in neuromuscular synapse maintenance and regeneration
US20100297652A1 (en) * 2009-05-22 2010-11-25 Asuragen, Inc. Mirna biomarkers of prostate disease
US20110028332A1 (en) * 2008-03-27 2011-02-03 Masahiko Kuroda Marker for diagnosis of breast cancer, test method, and test kit
US20110053158A1 (en) * 2009-08-28 2011-03-03 Asuragen, Inc. Mirna biomarkers of lung disease
US20120095082A1 (en) * 2009-06-29 2012-04-19 Assistance Publique-Hopitaux De Paris Use of interfering rna for treating an hiv infection
US20120108650A1 (en) * 2010-10-29 2012-05-03 Emory University Micro rna markers and methods related thereto
EP2484779A1 (en) 2011-02-03 2012-08-08 Medizinische Hochschule Hannover Device and method for analysis of kidney failure
US20120289420A1 (en) * 2011-03-18 2012-11-15 University Of South Florida Microrna biomarkers for airway diseases
WO2013060894A1 (en) * 2011-10-27 2013-05-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment and diagnosis of atherosclerosis
US20130236437A1 (en) * 2010-11-11 2013-09-12 Nanette Bishopric Compositions, kits and methods for treatment of cardiovascular, immunological and inflammatory diseases
US20130331436A1 (en) * 2010-12-06 2013-12-12 Rush University Medical Center Micrornas as new therapeutic targets for the prevention and/or treatment of retinopathy
EP2682477A1 (en) * 2012-07-06 2014-01-08 National University of Ireland, Galway miR-181a and miR652 as oncologic biomarker of breast cancer
US8642751B2 (en) 2010-12-15 2014-02-04 Miragen Therapeutics MicroRNA inhibitors comprising locked nucleotides
US8716258B2 (en) 2010-06-04 2014-05-06 The Board Of Regents, The University Of Texas System Regulation of metabolism by miR-378
US20140256792A1 (en) * 2011-10-17 2014-09-11 Pharmahungary 2000 Kft. Compounds for the treatment of ischemic injury
JP2014530619A (ja) * 2011-10-21 2014-11-20 ホスピタル クリニク デ バルセロナ 早期結腸直腸癌の検出のための血漿マイクロｒｎａ
US20150011414A1 (en) * 2012-01-16 2015-01-08 Herlev Hospital Microrna for diagnosis of pancreatic cancer and/or prognosis of patients with pancreatic cancer by blood samples
US20150080244A1 (en) * 2011-10-19 2015-03-19 Council Of Scientific And Industrial Research Biomarkers useful for detection of types, grades and stages of human breast cancer
KR101520545B1 (ko) 2013-09-06 2015-05-15 가천대학교 산학협력단 근육염증 진단용 조성물 및 그의 용도
WO2015134631A3 (en) * 2014-03-04 2015-11-26 Medlmmune, Llc Compositions and methods for identifying b cell malignancies responsive to b cell depleting therapy
CN105441566A (zh) * 2016-01-04 2016-03-30 中南民族大学 用于肝癌术后预后评估的试剂盒和肝癌化疗增敏剂
US9334498B2 (en) 2012-05-10 2016-05-10 Uab Research Foundation Methods and compositions for modulating MIR-204 activity
US9388408B2 (en) 2012-06-21 2016-07-12 MiRagen Therapeutics, Inc. Oligonucleotide-based inhibitors comprising locked nucleic acid motif
US9428749B2 (en) 2011-10-06 2016-08-30 The Board Of Regents, The University Of Texas System Control of whole body energy homeostasis by microRNA regulation
US9885042B2 (en) 2015-01-20 2018-02-06 MiRagen Therapeutics, Inc. miR-92 inhibitors and uses thereof
US20180251837A1 (en) * 2015-09-02 2018-09-06 Ikdt Institut Kardiale Diagnostik Und Therapie Gmbh Use of mirco-rnas circulating in the blood serum or blood plasma for identifying patients requiring a biopsy and as a marker for the differential diagnosis of individual non-ischemic cardiomyopathies or storage diseases
US20180305754A1 (en) * 2015-07-14 2018-10-25 Korea Institure Of Science And Technology Biomarker for diagnosis of drug addiction and kit for diagnosis of drug addiction
CN113373216A (zh) * 2021-07-13 2021-09-10 南京迈迪森亚生物科技有限公司 一种同时定量检测血清中3种急性心肌梗死相关microRNA荧光探针的制备方法
CN114525331A (zh) * 2021-11-23 2022-05-24 中山大学 一种快速识别重症肺炎的检测产品
WO2023092927A1 (zh) * 2021-09-08 2023-06-01 中国人民解放军空军军医大学 一种用于缓解应激性高血压血管内皮功能障碍的小rna及应用
CN116763809A (zh) * 2023-05-31 2023-09-19 广东医科大学附属医院 miR-376b-3p的抑制物在制备治疗癫痫药物中的应用

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101475984A (zh) 2008-12-15 2009-07-08 江苏命码生物科技有限公司 一种非小细胞肺癌检测标记物及其检测方法、相关生物芯片和试剂盒
EP2336353A1 (en) 2009-12-17 2011-06-22 febit holding GmbH miRNA fingerprints in the diagnosis of diseases
EP2450454A4 (en) * 2009-06-30 2012-11-14 Fujirebio Kk METHOD FOR ASSESSING THE CULTIVATED CELLS, AND METHOD FOR EXAMINING A BIOMARKER
CN101988120A (zh) * 2009-07-30 2011-03-23 江苏命码生物科技有限公司 一种利用血清中的微小核糖核酸诊断肝癌的新技术
CN102080082B (zh) * 2009-12-01 2013-05-22 中国科学院上海药物研究所 人miR-129＊反义核酸及其应用
DK3150721T3 (da) * 2009-12-24 2019-07-01 Micromedmark Biotech Co Ltd Pankreascancermarkører og detekteringsfremgangsmåder
US20130130927A1 (en) * 2010-03-11 2013-05-23 Helen Heneghan Detection and quantification of micrornas in the circulation and the use of circulating micrornas as biomarkers for cancer
ITMI20101089A1 (it) * 2010-06-16 2011-12-17 Istituto Naz Di Genetica Molecolare Ingm Profili di espressione di micro-rna nel sangue periferico per il monitoraggio del sistema immunitario
WO2012009508A2 (en) * 2010-07-15 2012-01-19 Emory University Microrna compositions and methods related thereto
CN102382823B (zh) * 2010-09-01 2013-04-24 中国科学院上海药物研究所 人miR-515-5p反义核酸及其应用
IT1405997B1 (it) * 2010-10-28 2014-02-06 Università Degli Studi Di Bari Metodo e kit per la diagnosi della iga nefropatia
CN102021167B (zh) * 2010-11-03 2013-02-27 南京大学 一种用于检测隐匿性乙型肝炎的血清miRNA组合物及其应用
JP5836397B2 (ja) * 2011-01-13 2015-12-24 インダストリアル テクノロジー リサーチ インスティテュートＩｎｄｕｓｔｒｉａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 結腸直腸がんの再発予測のためのバイオマーカー
WO2012105826A1 (en) * 2011-02-01 2012-08-09 Erasmus University Medical Center Rotterdam Use of micrornas in diagnosis and therapy of aging
CN102268483A (zh) * 2011-08-10 2011-12-07 中国人民解放军军事医学科学院基础医学研究所 一种利用miRNA-210为标志物的早期低氧检测试剂盒
CN102433375A (zh) * 2011-09-01 2012-05-02 中国药科大学 一种与药源性肝损伤相关的微小核糖核酸标志物及其检测试剂盒
CN102732619B (zh) * 2012-06-06 2014-04-23 中山大学肿瘤防治中心 一种miRNA的原位杂交探针及其检测试剂盒和应用
JP5933010B2 (ja) * 2012-08-20 2016-06-08 国立研究開発法人国立がん研究センター 癌治療剤
CN103602678B (zh) * 2013-06-18 2016-02-10 潘世扬 非小细胞肺癌预后检测组合物及其应用
CN105132525B (zh) * 2014-05-29 2018-11-09 中国医学科学院基础医学研究所 miRNA分子在精神分裂症的诊断和预后中的用途
CN104906125B (zh) * 2015-04-15 2018-03-02 中国人民解放军第二军医大学 microRNA‑326的抑制剂在制备治疗白内障的药物中的应用
CN108138180A (zh) 2015-06-05 2018-06-08 米拉根医疗股份有限公司 用于治疗皮肤t细胞淋巴瘤（ctcl）的mir-155抑制剂
KR101643748B1 (ko) * 2015-08-13 2016-07-29 충남대학교산학협력단 결핵 진단용 바이오마커 마이크로 rna
WO2017058938A1 (en) * 2015-09-29 2017-04-06 Research Institute At Nationwide Children's Hospital Methods for detecting hepatic fibrosis and responsiveness to therapy
TWI696703B (zh) * 2015-09-30 2020-06-21 中央研究院 用以診斷心肌梗塞的方法及套組
CN106282360B (zh) * 2016-08-31 2019-11-08 武汉博杰生物医学科技有限公司 一种用于结肠癌预测转移的血浆miRNA组合、其探针组合物及应用
WO2018165532A1 (en) * 2017-03-10 2018-09-13 Baylor Research Institute Methods for diagnosing and treating gastric cancer using mirna expression
CN107604063B (zh) * 2017-09-07 2020-09-04 青岛大学 miRNA-633和miRNA-633抑制剂的应用及应用其的产品
CN108546752B (zh) * 2018-04-20 2021-08-31 南京医科大学 检测和/或预测人类巨大儿的miRNA标志物或其组合及其应用
CN109536601B (zh) * 2018-12-21 2021-08-17 杭州师范大学 儿童哮喘血清特异miRNAs及决策树模型的建模方法
CN111778341B (zh) * 2020-07-28 2023-07-04 广东医科大学 一种活动性肺结核的生物标志物及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090004668A1 (en) * 2007-06-22 2009-01-01 The Board Of Trustees Of The Leland Stanford Junior University Pre-miRNA loop-modulated target regulation
US20090010908A1 (en) * 2005-02-01 2009-01-08 John Gow Materials and Methods for Diagnosis and Treatment of Chronic Fatigue Syndrome

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE283353T1 (de) * 1997-06-12 2004-12-15 Sloan Kettering Inst Cancer Kovalente bindung von dna zu rna strängen katalysiert durch vaccinia topoisomerase
US20080045417A1 (en) * 2003-10-14 2008-02-21 Jan Weiler Oligonucleotide Microarray
EP2290071B1 (en) * 2004-05-28 2014-12-31 Asuragen, Inc. Methods and compositions involving microRNA
CN100335655C (zh) * 2004-09-03 2007-09-05 中国科学院上海生命科学研究院 一种检测小分子rna的寡核苷酸微阵列芯片
CA2633754C (en) * 2006-01-05 2013-06-18 The Ohio State University Research Foundation Microrna-based methods and compositions for the diagnosis and treatment of solid cancers
SI2056845T1 (en) * 2006-08-08 2018-02-28 Rheinische Friedrich-Wilhelms-Universitaet Bonn STRUCTURE AND USE 5 'PHOSPHATE OF OLIGONUCLEOTES
WO2008057234A2 (en) * 2006-10-24 2008-05-15 The Board Of Trustees Of The Leland Stanford Junior University Modulation of t cell signaling threshold and t cell sensitivity to antigens
JPWO2008084319A1 (ja) * 2006-12-18 2010-04-30 協和発酵キリン株式会社 新規核酸
CN100999765A (zh) * 2006-12-20 2007-07-18 南京大学 以微小核糖核酸的变化鉴定结肠癌化程度的生物芯片
US8709791B2 (en) * 2007-02-09 2014-04-29 Stc.Unm Detection of bioagents using a shear horizontal surface acoustic wave biosensor
WO2009015357A1 (en) * 2007-07-25 2009-01-29 University Of Louisville Research Foundation, Inc. Exosome-associated microrna as a diagnostic marker
US20090239818A1 (en) * 2007-09-07 2009-09-24 Cheng Jin Q Effective treatment of ovarian cancer using triciribine and related compounds
WO2009036332A1 (en) * 2007-09-14 2009-03-19 Asuragen, Inc. Micrornas differentially expressed in cervical cancer and uses thereof
EP3112464A1 (en) * 2007-09-14 2017-01-04 The Ohio State University Research Foundation Mirna expression in human peripheral blood microvesicles and uses thereof
WO2009044899A1 (ja) * 2007-10-03 2009-04-09 Kyowa Hakko Kirin Co., Ltd. 細胞の増殖を制御する核酸
EP2268832A2 (en) * 2008-03-06 2011-01-05 Asuragen, INC. Microrna markers for recurrence of colorectal cancer
SG182365A1 (en) * 2010-01-12 2012-08-30 Univ Yale Structured rna motifs and compounds and methods for their use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090010908A1 (en) * 2005-02-01 2009-01-08 John Gow Materials and Methods for Diagnosis and Treatment of Chronic Fatigue Syndrome
US20090004668A1 (en) * 2007-06-22 2009-01-01 The Board Of Trustees Of The Leland Stanford Junior University Pre-miRNA loop-modulated target regulation

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Calin et al., Cancer Res., Vol. 66, No. 15, pages 7390-7394 (2006). *
Doench et al., Genes and Development, Vol. 18, No. 5, pages 504-511 (2004). *
Kruhoffer et al., J. Molecular Diagnostics, Vol. 9, No. 4, pages 452-458 (2007). *
Opalinska et al., Nature Rev., Vol. 1, pages 503-514 (2002). *

Cited By (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8202848B2 (en) 2008-03-17 2012-06-19 Board Of Regents, The University Of Texas System Identification of micro-RNAS involved in neuromuscular synapse maintenance and regeneration
US8728724B2 (en) 2008-03-17 2014-05-20 Board Of Regents, The University Of Texas System Identification of micro-RNAs involved in neuromuscular synapse maintenance and regeneration
US20090246136A1 (en) * 2008-03-17 2009-10-01 Andrew Williams Identification of micro-rnas involved in neuromuscular synapse maintenance and regeneration
US20110028332A1 (en) * 2008-03-27 2011-02-03 Masahiko Kuroda Marker for diagnosis of breast cancer, test method, and test kit
US20100297652A1 (en) * 2009-05-22 2010-11-25 Asuragen, Inc. Mirna biomarkers of prostate disease
US8597892B2 (en) 2009-05-22 2013-12-03 Asuragen, Inc. MiRNA biomarkers of prostate disease
US20120095082A1 (en) * 2009-06-29 2012-04-19 Assistance Publique-Hopitaux De Paris Use of interfering rna for treating an hiv infection
US9127279B2 (en) * 2009-06-29 2015-09-08 Universite Pierre Et Marie Curie (Paris 6) Use of interfering rna for treating an hiv infection
US8735074B2 (en) 2009-08-28 2014-05-27 Asuragen, Inc. MiRNA biomarkers of lung disease
US20110053158A1 (en) * 2009-08-28 2011-03-03 Asuragen, Inc. Mirna biomarkers of lung disease
US8716258B2 (en) 2010-06-04 2014-05-06 The Board Of Regents, The University Of Texas System Regulation of metabolism by miR-378
US20120108650A1 (en) * 2010-10-29 2012-05-03 Emory University Micro rna markers and methods related thereto
US9248144B2 (en) * 2010-11-11 2016-02-02 University Of Miami Compositions, kits and methods for treatment of cardiovascular, immunological and inflammatory diseases
US20130236437A1 (en) * 2010-11-11 2013-09-12 Nanette Bishopric Compositions, kits and methods for treatment of cardiovascular, immunological and inflammatory diseases
US9944989B2 (en) 2010-12-06 2018-04-17 Rush University Medical Center Micrornas as new therapeutic targets for the prevention and/or treatment of retinopathy
US20130331436A1 (en) * 2010-12-06 2013-12-12 Rush University Medical Center Micrornas as new therapeutic targets for the prevention and/or treatment of retinopathy
US8642751B2 (en) 2010-12-15 2014-02-04 Miragen Therapeutics MicroRNA inhibitors comprising locked nucleotides
EP2484779A1 (en) 2011-02-03 2012-08-08 Medizinische Hochschule Hannover Device and method for analysis of kidney failure
EP2505667A2 (en) 2011-02-03 2012-10-03 Medizinische Hochschule Hannover Device and method for analysis of kidney failure
US20120289420A1 (en) * 2011-03-18 2012-11-15 University Of South Florida Microrna biomarkers for airway diseases
US9428749B2 (en) 2011-10-06 2016-08-30 The Board Of Regents, The University Of Texas System Control of whole body energy homeostasis by microRNA regulation
US20140256792A1 (en) * 2011-10-17 2014-09-11 Pharmahungary 2000 Kft. Compounds for the treatment of ischemic injury
US9457046B2 (en) * 2011-10-17 2016-10-04 PharmalHungary 2000 Kft. Compounds for the treatment of ischemic injury
US10208353B2 (en) * 2011-10-19 2019-02-19 Council Of Scientific And Industrial Research Biomarkers useful for detection of types, grades and stages of human breast cancer
US20150080244A1 (en) * 2011-10-19 2015-03-19 Council Of Scientific And Industrial Research Biomarkers useful for detection of types, grades and stages of human breast cancer
US11136628B2 (en) 2011-10-19 2021-10-05 Council Of Scientific And Industrial Research Biomarkers useful for detection of types, grades and stages of human breast cancer
JP2014530619A (ja) * 2011-10-21 2014-11-20 ホスピタル クリニク デ バルセロナ 早期結腸直腸癌の検出のための血漿マイクロｒｎａ
US20150176082A1 (en) * 2011-10-21 2015-06-25 Hospital Clínic De Barcelona Plasma micrornas for the detection of early colorectal cancer
WO2013060894A1 (en) * 2011-10-27 2013-05-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment and diagnosis of atherosclerosis
US20150011414A1 (en) * 2012-01-16 2015-01-08 Herlev Hospital Microrna for diagnosis of pancreatic cancer and/or prognosis of patients with pancreatic cancer by blood samples
US9334498B2 (en) 2012-05-10 2016-05-10 Uab Research Foundation Methods and compositions for modulating MIR-204 activity
US10337005B2 (en) 2012-06-21 2019-07-02 MiRagen Therapeutics, Inc. Oligonucleotide-based inhibitors comprising locked nucleic acid motif
US9388408B2 (en) 2012-06-21 2016-07-12 MiRagen Therapeutics, Inc. Oligonucleotide-based inhibitors comprising locked nucleic acid motif
US9803202B2 (en) 2012-06-21 2017-10-31 MiRagen Therapeutics, Inc. Oligonucleotide-based inhibitors comprising locked nucleic acid motif
EP2682477A1 (en) * 2012-07-06 2014-01-08 National University of Ireland, Galway miR-181a and miR652 as oncologic biomarker of breast cancer
WO2014006160A1 (en) 2012-07-06 2014-01-09 National University Of Ireland, Galway A mirna oncologic biomarker of breast cancer
KR101520545B1 (ko) 2013-09-06 2015-05-15 가천대학교 산학협력단 근육염증 진단용 조성물 및 그의 용도
CN106460036A (zh) * 2014-03-04 2017-02-22 免疫医疗有限责任公司 用于对响应b细胞消耗疗法的b细胞恶性肿瘤进行鉴定的组合物和方法
WO2015134631A3 (en) * 2014-03-04 2015-11-26 Medlmmune, Llc Compositions and methods for identifying b cell malignancies responsive to b cell depleting therapy
US9885042B2 (en) 2015-01-20 2018-02-06 MiRagen Therapeutics, Inc. miR-92 inhibitors and uses thereof
US10280422B2 (en) 2015-01-20 2019-05-07 MiRagen Therapeutics, Inc. MiR-92 inhibitors and uses thereof
US20180305754A1 (en) * 2015-07-14 2018-10-25 Korea Institure Of Science And Technology Biomarker for diagnosis of drug addiction and kit for diagnosis of drug addiction
US20180251837A1 (en) * 2015-09-02 2018-09-06 Ikdt Institut Kardiale Diagnostik Und Therapie Gmbh Use of mirco-rnas circulating in the blood serum or blood plasma for identifying patients requiring a biopsy and as a marker for the differential diagnosis of individual non-ischemic cardiomyopathies or storage diseases
CN105441566A (zh) * 2016-01-04 2016-03-30 中南民族大学 用于肝癌术后预后评估的试剂盒和肝癌化疗增敏剂
CN113373216A (zh) * 2021-07-13 2021-09-10 南京迈迪森亚生物科技有限公司 一种同时定量检测血清中3种急性心肌梗死相关microRNA荧光探针的制备方法
WO2023092927A1 (zh) * 2021-09-08 2023-06-01 中国人民解放军空军军医大学 一种用于缓解应激性高血压血管内皮功能障碍的小rna及应用
CN114525331A (zh) * 2021-11-23 2022-05-24 中山大学 一种快速识别重症肺炎的检测产品
CN116763809A (zh) * 2023-05-31 2023-09-19 广东医科大学附属医院 miR-376b-3p的抑制物在制备治疗癫痫药物中的应用

Also Published As

Publication number Publication date
DK2133431T3 (da) 2012-11-05
CN101424640B (zh) 2012-07-25
WO2009055979A1 (fr) 2009-05-07
US10011880B2 (en) 2018-07-03
IL195324A (en) 2013-03-24
US20140121133A1 (en) 2014-05-01
EP2133431A1 (en) 2009-12-16
US20160273054A1 (en) 2016-09-22
US10077477B2 (en) 2018-09-18
CN101424640A (zh) 2009-05-06
IL195324A0 (en) 2011-08-01
EP2133431A4 (en) 2011-02-23
EP2133431B1 (en) 2012-08-22

Similar Documents

Publication Publication Date Title
US10011880B2 (en) Serum/plasma MicroRNAs and uses thereof
US20180230546A1 (en) Reagents and Methods for miRNA Expression Analysis and Identification of Cancer Biomarkers
AU2012245580B2 (en) miRNA-based universal screening test (UST)
CN101386848A (zh) 细胞微粒子所载微小核糖核酸及其制备研究方法和应用
US7811759B2 (en) Method for detecting ncRNA
US9821009B2 (en) Method for modulating microRNA content in living beings and the use thereof
CN101921759B (zh) 一种与宫颈癌及其癌前病变相关的血清/血浆miRNA标志物及其应用
US9388470B2 (en) Serum or plasma microRNA as biomarkers for non-small cell lung cancer
US20150376711A1 (en) Methods of detecting lung cancer
JP2013502931A5 (zh)
JP2010533501A (ja) 小さなｒｎａ分子を定量するための方法
US20130072393A1 (en) Pancreatic cancer markers, and detecting methods, kits, biochips thereof
WO2011012074A1 (zh) 肝癌检测标记物及其检测方法、试剂盒和生物芯片
Taylor Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol. Jul
US20210079478A1 (en) Method for assisting in detection of breast cancer
CN114196759B (zh) 一种尿液样本的胰腺癌生物标志物及其应用
CN114807375A (zh) 一种尿液样本的黑色素瘤生物标志物及其应用

Legal Events

Date Code Title Description
AS Assignment

Owner name: JIANGSU MINGMA BIOTECH CO., LTD., CHINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ZHANG, CHEN-YU;ZHANG, JUNFENG;CHEN, XI;AND OTHERS;SIGNING DATES FROM 20081021 TO 20081103;REEL/FRAME:021885/0751

AS Assignment

Owner name: JIANGSU MINGMA BIOTECH CO., LTD., CHINA

Free format text: RE-RECORD TO CORRECT THE EXECUTION DATE OF THE FIRST ASSIGNOR, PREVIOUSLY RECORDED ON REEL 021885 FRAME 0751;ASSIGNORS:ZHANG, CHEN-YU;ZHANG, JUNFENG;CHEN, XI;AND OTHERS;SIGNING DATES FROM 20081031 TO 20081103;REEL/FRAME:022013/0742

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION